In the AT size change ratio, it is presumed that the anti-tumor effect of the anti-PD-1 antibody was too strong, and the tumor size reduction almost reached a plateau before the endpoint, so the comparison of AT size change ratio did not confirm the synergistic effect. This evidence concerns the gene PDCD1 and neoplasm.